Entera Bio Ltd.

Equities

ENTX

IL0011429839

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1.9 ^USD	-0.52%		+13.77%	+216.67%

May. 15	Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	CI
May. 13	Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024	CI

Entera Bio Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2018

January 22, 2019 at 08:07 am EST

Entera Bio Ltd. announced earnings results for the third quarter ended September 30, 2018. For the third quarter, the company announced operating loss was USD 2.866 million compared to USD 2.779 million a year ago. Net loss was USD 5.066 million compared to USD 3.656 million a year ago. For the nine months, operating loss was USD 8.378 million compared to USD 6.953 million a year ago. Net loss was USD 7.659 million compared to USD 7.422 million a year ago.

Latest news about Entera Bio Ltd.

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	May. 15	CI
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024	May. 13	CI
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research	Apr. 08	CI
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months	Mar. 26	CI
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Top Premarket Gainers	Jan. 18	MT
Top Premarket Gainers	Jan. 17	MT
Entera Bio Ltd. announced that it has received $6.610594 million in funding	Dec. 21	CI
Entera Bio Ltd. announced that it expects to receive $6.610594 million in funding	Dec. 19	CI
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform	Nov. 29	CI
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide Phase 3 Program	Nov. 09	CI
Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting	23-10-16	CI
Entera Bio Ltd. Announces Collaboration with OPKO Biologics, Inc. to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes	23-09-12	CI
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research Annual Meeting	23-08-16	CI
Entera Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Entera Bio Ltd Adds Haya Taitel to its Board of Directors	23-06-07	CI
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics	23-05-03	CI
Steven R. Goldstein Joins Entera Bio Ltd.'s Clinical and Scientific Advisory Board	23-04-26	CI
Entera Bio Ltd. Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program	23-04-03	CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Entera Bio Ltd. Auditor Raises 'Going Concern' Doubt	23-03-30	CI

Chart Entera Bio Ltd.

Duration

Period

More charts

Company Profile

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Sector

Biotechnology & Medical Research

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.9 USD

Average target price

10 USD

Spread / Average Target

+426.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENTERA BIO LTD.	+216.67%	68.47M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs